Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages
Apogee Therapeutics Inc. (NASDAQ:APGE) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month price target of $104.58. This comes despite significant insider selling, including Fairmount Funds Management selling 1.75 million shares and the CEO selling 20,000 shares, totaling over $143 million in the last 90 days. Apogee is a clinical-stage biotechnology company focused on developing an oral treatment for plaque psoriasis.
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
Jefferies lowered its price target on Apogee Therapeutics Inc. (NASDAQ:APGE) to $95 from $98, maintaining a Buy rating, following a 6% drop in the company's share price. This adjustment occurred after Amgen discontinued its OX40 collaboration and Sanofi deprioritized amlitelimab for certain non-atopic dermatitis indications. The analyst also reduced the risk-adjusted peak sales forecast for Apogee’s ’279 combination therapy from $1.8 billion to $1.6 billion, citing potential limitations for high-risk patients.
Technical Reactions to APGE Trends in Macro Strategies
This article provides a technical analysis of Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting a positive near-term sentiment while noting a mid-term weak bias within a long-term strength context. It details institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis for support and resistance levels. The analysis also identifies a significant risk-reward short setup.
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc
Michael Henderson, CEO of Apogee Therapeutics Inc (APGE), sold 20,000 shares of the company on February 11, 2026, reducing his total holdings to 1,172,987 shares. This transaction is part of a pattern over the past year, during which Henderson has sold a total of 120,000 shares with no purchases. Apogee Therapeutics Inc, a biopharmaceutical company, saw its shares trading at $63.35, resulting in a market cap of $4.63 billion on the day of the sale.
Apogee Therapeutics CEO Sells 20,000 Shares
Michael Thomas Henderson, CEO and Director of Apogee Therapeutics (APGE), sold 20,000 shares of common stock on February 11, 2026, for a total of $1,266,952. The shares were sold under a Rule 10b5-1 trading plan at weighted average prices between $62.96 and $64.99. Following the transactions, Henderson directly owns 1,172,987 shares of the company.
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock
Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares of APGE stock on February 11th for $1.267 million, reducing his ownership by 1.68%. This sale is part of a pattern of recent insider selling, totaling 100,000 shares over several months. Despite the insider sales, analysts have a "Moderate Buy" rating on APGE with an average price target of $104.58.
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference
Apogee Therapeutics outlined its strategy at Guggenheim’s Emerging Outlook Biotech Conference, aiming to shift atopic dermatitis (AD) treatment to less frequent, quarterly-to-biannual dosing, with Phase III trials planned for this year and a target 2029 launch. The company also announced plans to pursue an asthma label following positive Phase 1b results showing significant and durable biomarker reduction, thereby expanding its market opportunity, especially considering the comorbidity between AD and asthma. Apogee is developing APG279, a fixed-dose co-formulation, to compete with Dupixent, supported by a strong cash runway into late 2028 and optimized manufacturing costs.
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE
Candriam S.C.A. has initiated a new position in Apogee Therapeutics Inc. by purchasing 126,081 shares valued at approximately $5.01 million, representing about 0.27% of the company. This investment comes amidst significant insider selling, with insiders offloading around 1.865 million shares totaling $142.3 million in the last three months. Despite insider sales, Wall Street analysts maintain a "Moderate Buy" consensus rating for Apogee Therapeutics, with an average target price of $104.58 against a recent stock price of $65.81.
Apogee Therapeutics stock hits 52-week high at 62.24 USD By Investing.com
Apogee Therapeutics Inc. has achieved a new 52-week high of $62.24, marking a 58.17% increase over the past year. This performance reflects strong investor confidence and positive market sentiment. Recent analyst updates show varied opinions, with some maintaining Buy ratings and increasing price targets, while others like RBC Capital downgraded the stock due to valuation concerns.
Apogee Therapeutics stock hits 52-week high at 62.24 USD
Apogee Therapeutics Inc. (APGE) has reached a new 52-week high of $62.24, marking a 58.17% increase in its stock price over the past year. This achievement is attributed to strong investor confidence and positive market sentiment surrounding the company's business prospects. Analyst firms like Jefferies, RBC Capital, Craig-Hallum, UBS, and Wolfe Research have provided varied updates on the stock, reflecting different perspectives on its future growth.
Trading the Move, Not the Narrative: (APGE) Edition
This article provides an AI-driven analysis for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with a multi-timeframe signal analysis and an exceptional risk-reward setup. The piece emphasizes exploiting market moves rather than narratives, using quantitative data to inform trading decisions for different risk profiles.
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock
Carl Dambkowski, an insider at Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares of the company's stock for $361,845 on February 4th, reducing his position by 2.54%. This sale is part of a pattern of recent insider selling, which has seen the stock trade down by 5.8%. Despite the insider sales, analysts generally rate Apogee Therapeutics as a "Moderate Buy" with a consensus price target of $104.58.
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com
Carl Dambkowski, CMO of Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares for $361,860 on February 4, 2026, while also exercising options for 4,125 shares. These transactions occurred as the stock experienced a short-term decline but maintained significant long-term gains. The sale was part of a pre-arranged trading plan, and the company has recently been the subject of varied analyst ratings following recent developments.
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Apogee Therapeutics announced that its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. A live and archived webcast will be available on the Investors section of their website. The company is a clinical-stage biotechnology firm developing novel biologics for various inflammatory and immunological conditions.
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Apogee Therapeutics announced that members of its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. The company is a clinical-stage biotechnology firm focused on developing novel biologics for inflammatory and immunological diseases. A webcast of the event will be available on their investor relations website.
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com
Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, sold 5,500 shares of the company's common stock for approximately $361,860, with transactions occurring between $64.88 and $68.94. This sale was made pursuant to a Rule 10b5-1 trading plan. Despite a recent 7.29% stock decline, the company has seen a 69.27% gain over the last six months, and Dambkowski still directly owns 211,148 shares after also exercising options to acquire 4,125 shares.
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
Apogee Therapeutics, a clinical-stage biotechnology company, announced that its management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company focuses on developing novel biologics for inflammatory and immunological (I&I) diseases, with its leading program, Zumilokibart (APG777), targeting Atopic Dermatitis and asthma. A webcast of the event will be available on the company's investor relations website.
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com
Jefferies has reduced its price target for Apogee Therapeutics (NASDAQ:APGE) to $95.00 from $98.00, while maintaining a Buy rating. This adjustment follows a 6% drop in Apogee shares due to concerns over OX40 collaboration changes by Amgen and Sanofi, though Jefferies believes Kaposi's Sarcoma concerns will not significantly impact OX40 therapy commercial potential. The firm slightly lowered its risk-adjusted peak sales forecast for Apogee’s ’279 combination therapy from $1.8 billion to $1.6 billion.
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE
Exane Asset Management has invested $2.05 million in Apogee Therapeutics Inc. (NASDAQ:APGE), acquiring 51,543 shares which now represent 0.7% of Exane's portfolio. Despite this new investment and other hedge funds increasing their stakes, there have been significant insider sales totaling over $143 million in the last 90 days. Analysts maintain a "Moderate Buy" rating for APGE with an average target price of $105.45, while the company trades near $72.38 and has a market cap of $4.95 billion.
(APGE) Volatility Zones as Tactical Triggers
This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE) using AI models to identify volatility zones as tactical triggers for traders. It highlights a weak near-term sentiment but strong long-term potential, presenting three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, each with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis indicating support and resistance levels, emphasizing the stock's 60.9:1 risk-reward setup.
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Moderate Buy" from Brokerages
Apogee Therapeutics Inc. (NASDAQ:APGE) has received an average rating of "Moderate Buy" from fourteen brokerages, with an average 12-month price target of $105.45. Despite this, company insiders, including the CEO, have recently sold a significant number of shares, totaling over $143 million in the last 90 days. The stock currently trades at $70.02, has a market cap of $4.78 billion, and analysts expect negative earnings per share for the current year.
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com
Fairmount Healthcare Fund II L.P. sold 1,750,000 shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) for $133.53 million on January 22, 2026, with the stock trading near its 52-week high after a significant run-up. Despite the sale, Fairmount Healthcare Fund II L.P. retains substantial holdings in Apogee, including convertible non-voting common stock. The article also touches on mixed analyst ratings and the company's strong financial position.
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling
Apogee Therapeutics (NASDAQ:APGE) shares dropped 10.2% after Director Fairmount Funds Management LLC sold 1,750,000 shares for approximately $133.5 million, significantly reducing its stake by over 85%. Despite the insider selling, analysts have mixed views on the stock, with an average "Moderate Buy" rating and a price target of $105.45. The company recently reported better-than-expected quarterly earnings and institutional investors have been adjusting their positions.
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares
Fairmount Funds Management LLC, a director at Apogee Therapeutics (NASDAQ:APGE), sold 1,750,000 shares of the company's stock on January 22nd at an average price of $76.30, totaling over $133.5 million. This transaction decreased their ownership by 85.42%. Apogee Therapeutics is a clinical-stage biotech focused on autoimmune and inflammatory skin diseases, with its lead candidate APG-157 in early-stage clinical evaluation for plaque psoriasis.
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million
Fairmount Healthcare Fund II L.P. sold 1,750,000 shares of Apogee Therapeutics (APGE) for $133.53 million on January 22, 2026, at $76.30 per share. This transaction occurred as APGE stock approached its 52-week high after a significant 99% return over the past year, though InvestingPro data suggests the company is overvalued. Post-sale, Fairmount still retains a substantial holding in Apogee, with managers Peter Harwin and Tomas Kiselak also holding direct shares.
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns
RBC Capital downgraded Apogee Therapeutics Inc (NASDAQ:APGE) from Outperform to Sector Perform due to valuation concerns, despite raising its price target to $83.00. The stock has seen a significant rise of over 100% in the past year, leading RBC Capital to believe that further near-term upside is not yet justified given the competitive landscape in the inflammatory and immunology spaces. Other analysts, however, have maintained positive outlooks and raised price targets for Apogee Therapeutics following promising results from its Phase 1b asthma trials for its lead drug, zumi.
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns
RBC Capital has downgraded Apogee Therapeutics (NASDAQ:APGE) from Outperform to Sector Perform due to valuation concerns, despite raising its price target to $83.00. The stock has seen a significant 108% increase over the past year, leading RBC to believe its current market capitalization of $5.53 billion is not yet justified for further near-term upside. However, the firm maintains a positive outlook on the company's lead drug, zumi, for atopic dermatitis and potential in asthma, expecting positive upcoming maintenance results.
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns
RBC Capital has downgraded Apogee Therapeutics Inc (NASDAQ:APGE) from Outperform to Sector Perform due to valuation concerns, despite raising its price target to $83.00. The stock has seen a significant 108% increase over the past year, leading to RBC Capital's view that its current market capitalization of $5.53 billion is not yet justified for further near-term upside. The firm maintains its positive outlook on the company's lead drug zumi, particularly for atopic dermatitis and potential asthma treatment, but notes increasing competition in the inflammatory and immunology spaces.
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE)
Michael Henderson, CEO of Apogee Therapeutics Inc (APGE), sold 20,000 shares of the company on January 14, 2026, reducing his total holdings to 1,192,987 shares. This transaction is part of a larger trend of insider selling at Apogee Therapeutics, with 0 insider buys and 22 insider sells over the past year. Shares were trading at $81.11 at the time of the sale, giving the company a market capitalization of $5.518 billion.
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares
Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares of the company's stock on January 14th for over $1.6 million, reducing his position by 1.65%. This sale is part of a pattern of insider selling by Henderson in recent months. Despite the insider selling, analysts maintain a "Moderate Buy" rating for APGE with an average target price of $104.27.
Apogee Therapeutics CEO Henderson sells $1.6m in stock
Apogee Therapeutics CEO Michael Thomas Henderson sold 14,400 shares of common stock for $1.62 million on January 14, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred while the stock (NASDAQ:APGE) traded near its 52-week high, having delivered a significant 117.94% return over the past year. Despite an InvestingPro analysis suggesting the biotech company is overvalued, it maintains strong financial health, and recent positive Phase 1b trial results have led several analysts to raise their price targets.
Price-Driven Insight from (APGE) for Rule-Based Strategy
This article provides a price-driven insight for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting near-term strong sentiment with potential for mid-term neutrality and a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels for APGE. The analysis also points out elevated downside risk due to a lack of additional long-term support signals.
Is Apogee's Pipeline Momentum Driving Investor Confidence?
Apogee Therapeutics (APGE) shares recently hit a new high, reflecting strong investor confidence driven by its promising clinical pipeline. The company is advancing Zumilokibart (APG777) for various inflammatory diseases, with key trial data expected throughout 2026, and is also exploring combination therapies. Apogee's robust financial position, bolstered by a $345 million public offering, is expected to fund operations into late 2028, supporting its clinical programs through pivotal stages.
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com
Apogee Therapeutics Inc. stock reached an all-time high of $81.0, surpassing its previous 52-week high, driven by strong investor confidence and significant growth in the past year. The company's impressive market performance is supported by positive analyst ratings and promising Phase 1b trial results for its asthma treatment, zumilokibart, indicating potential for further upside.
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com
Apogee Therapeutics Inc. (APGE) stock reached an all-time high of $81.0, exceeding its previous 52-week high, driven by strong investor confidence and significant growth. The company has seen a 100.81% increase over the past year and a 103.19% return over the last six months. Analysts maintain a bullish outlook, with high price targets, following promising Phase 1b trial results for its asthma treatment, zumilokibart.
SG Americas Securities LLC Invests $5.33 Million in Apogee Therapeutics Inc. $APGE
SG Americas Securities LLC has initiated a new position in Apogee Therapeutics Inc. (NASDAQ:APGE), acquiring 134,226 shares valued at approximately $5.33 million which represents about 0.29% of the company. Despite recent insider selling, including significant sales by the CEO and another insider, analysts maintain a "Moderate Buy" consensus with an average target price of $104.27, suggesting potential upside from the current share price. Apogee Therapeutics' stock has shown an upward trend, with a market capitalization of $5.33 billion.
Assessing Apogee Therapeutics (APGE) Valuation After Positive Phase 1b Asthma Trial Data And 2026 Pipeline Milestones
Apogee Therapeutics (APGE) is under scrutiny after positive interim Phase 1b data for its asthma drug, zumilokibart, leading to a strong share price performance and several clinical milestones planned for 2026. The company's valuation, marked by a 9x price-to-book multiple, suggests investors are focused on future potential despite current losses and zero revenue. While appearing expensive compared to the broader US biotech industry, Apogee trades at a discount to its direct peers, indicating a premium assigned by investors for its niche.
A Look At Apogee Therapeutics (APGE) Valuation After Positive Asthma Trial Update And 2026 Pipeline Milestones
Apogee Therapeutics (APGE) is gaining investor attention following positive interim Phase 1b data for its asthma candidate, zumilokibart, and an ambitious clinical pipeline set for 2026. The company's stock has seen significant momentum, with a 48.64% return over 90 days, and it currently trades at a 32% discount to analyst targets. Despite a high price-to-book ratio of 9x compared to the broader US biotech industry average, its valuation reflects expectations for future clinical and commercial success amidst ongoing net losses.
Wolfe Research Initiates Coverage of Apogee Therapeutics (APGE) with Peer Perform Recommendation
Wolfe Research has initiated coverage of Apogee Therapeutics (APGE) with a "Peer Perform" recommendation. Analysts forecast an average one-year price target of $99.45/share, suggesting a 27.09% upside from its latest reported closing price of $78.25. Institutional ownership has increased, with a bullish put/call ratio of 0.55, indicating positive sentiment from funds.
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data
Craig-Hallum has increased its price target for Apogee Therapeutics Inc (NASDAQ:APGE) from $109.00 to $116.00, maintaining a Buy rating on the stock, following promising Phase 1b data for its zumilokibart (APG777) program in asthma patients. The firm highlighted the treatment's durability and broad applicability, suggesting potential for dosing intervals of three to six months. Other analysts like BTIG, RBC Capital, and UBS also expressed optimism, raising price targets or initiating Buy ratings, while Wolfe Research provided a Peerperform rating based on valuation.
UBS initiates Apogee Therapeutics stock with Buy rating, $100 target By Investing.com
UBS has initiated coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and a $100 price target, citing the company's strong financial position and the potential of its lead candidate, APG777, in immunology and inflammation. The investment bank highlights APG777's rare dosing profile and early efficacy data, along with several major clinical readouts expected in 2026 that could de-risk the pipeline and drive stock growth. This positive outlook follows other analysts' bullish sentiments, including BTIG raising its price target to $137 after positive Phase 1b asthma trial results for zumilokibart.
Wolfe Research initiates coverage on Apogee Therapeutics stock with Peerperform rating
Wolfe Research has initiated coverage on Apogee Therapeutics Inc (NASDAQ:APGE) with a Peerperform rating, noting the company's significant stock momentum and an InvestingPro analysis indicating the stock might be overvalued. Despite concerns regarding the commercial landscape for mass-market immunology treatments, Wolfe Research expects clinical trial data to be the primary driver of the stock's performance through 2026. This comes after Apogee Therapeutics announced positive interim results from its Phase 1b trial for an asthma treatment, leading to raised price targets from other analyst firms like BTIG and RBC Capital.
Craig-Hallum raises Apogee Therapeutics stock price target on promising asthma data
Craig-Hallum increased its price target for Apogee Therapeutics (NASDAQ:APGE) to $116 from $109, maintaining a Buy rating, following promising Phase 1b data for its zumilokibart (APG777) asthma program. This data validates the treatment's durability and breadth, suggesting potential for wider applications. Other analysts like BTIG, RBC Capital, and UBS have also shown optimism with increased price targets or positive ratings, while Wolfe Research remains Peerperform.
March 20th Options Now Available For Apogee Therapeutics (APGE)
New options for Apogee Therapeutics (APGE) with a March 20th expiration are now available, offering opportunities for investors. The article details potential strategies for put and call contracts, including a $75.00 strike put with a 60% chance of expiring worthless and an $80.00 strike call with a 47% chance of expiring worthless, both offering significant annualized returns if unexercised. It also highlights the implied and trailing twelve-month volatilities for APGE.
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
Apogee Therapeutics announced it will report interim results from its Phase 1b trial of APG777 for mild-to-moderate asthma and discuss 2026 anticipated milestones on January 6, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss these results. APG777 is Apogee's most advanced program, aimed at treating inflammatory and immunological diseases.
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial
Apogee Therapeutics' drug, zumilokibart (APG777), demonstrated robust and durable suppression of FeNO, a key biomarker for Type 2 inflammation in asthma, in a Phase 1b trial. A single dose showed FeNO reduction lasting up to 32 weeks, suggesting potential for 3- or 6-month dosing intervals. The drug was well-tolerated, and positive trends in lung function were observed.
Apogee Therapeutics to report interim asthma trial results By Investing.com
Apogee Therapeutics (NASDAQ:APGE) will announce interim results from its Phase 1b trial for APG777, targeting mild-to-moderate asthma, on Tuesday, January 6, 2026. The company, which specializes in optimized biologics for inflammatory and immunology conditions, will host a conference call and webcast to discuss the findings. This news follows recent positive developments, including promising interim results for APG333 and favorable coverage from multiple financial analysts.
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose
Apogee Therapeutics (NASDAQ: APGE) presented interim Phase 1b data for its IL-13 antibody zumilokibart (APG777) in mild to moderate asthma, showing a robust and durable reduction in fractional exhaled nitric oxide (FeNO) after a single 720 mg dose. The treatment resulted in a mean FeNO drop of 45 ppb, sustained through 16 weeks for all patients and up to 32 weeks in a subset, with a safety profile consistent with expectations. These results position APG777 as potentially comparable to existing treatments and represent the first of four key clinical catalysts for Apogee in 2026, with plans for dual atopic dermatitis/asthma labeling and longer dosing intervals.
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data
BTIG has raised its price target for Apogee Therapeutics Inc. to $137 from $128, maintaining a Buy rating, following positive Phase 1b asthma trial results for its zumilokibart treatment. The drug showed significant and durable reductions in FeNO in mild-to-moderate asthma patients, outperforming competitors, with no observed conjunctivitis adverse events. Apogee's strong financial position and other promising pipeline developments, such as APG273 and APG333, further reinforce the positive outlook.
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data
RBC Capital has reaffirmed its Outperform rating and $70.00 price target for Apogee Therapeutics Inc (NASDAQ:APGE) following positive Phase 1b study data for its APG-777 drug candidate in asthma. Despite the stock trading above RBC's target at $76.59, the firm remains bullish due to promising portfolio developments and potential de-risking data expected this year. Other analysts like BTIG and Deutsche Bank have also issued Buy ratings with higher price targets, highlighting confidence in Apogee's potential in inflammatory and immunology diseases.
